Fluoro substituted 2-oxo-azepan derivatives
    1.
    发明申请
    Fluoro substituted 2-oxo-azepan derivatives 失效
    氟取代的2-氧代 - 氮杂环庚烷衍生物

    公开(公告)号:US20070037789A1

    公开(公告)日:2007-02-15

    申请号:US11500662

    申请日:2006-08-08

    IPC分类号: A61K31/55 C07D223/12

    摘要: The invention relates to compounds of general formula wherein R1, R2, R3/R3′, R4/R4′ and R5/R5′ are as defined in the specification and to pharmaceutically acceptable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. The compounds are γ-secretase inhibitors which can be useful in the treatment of Alzheimer's disease or common cancers including, but not limited to, cervical carcinomas and breast carcinomas and malignancies of the hematopoietic system.

    摘要翻译: 本发明涉及通式的化合物,其中R 1,R 2,R 3,R 3,R 3, R 4 / R 4'和R 5 / R 5'如说明书中所定义,并且在药学上 可接受的酸加成盐,旋光纯对映异构体,外消旋物或非对映体混合物。 该化合物是γ-分泌酶抑制剂,其可用于治疗阿尔茨海默病或常见癌症,包括但不限于宫颈癌和乳腺癌以及造血系统的恶性肿瘤。

    Sulfonamides
    2.
    发明申请
    Sulfonamides 失效
    磺胺类

    公开(公告)号:US20060014945A1

    公开(公告)日:2006-01-19

    申请号:US11179703

    申请日:2005-07-12

    IPC分类号: A61K31/55 C07D223/10

    CPC分类号: C07D223/12 C07D403/12

    摘要: The invention relates to compounds of the general formula in which R1, R2, R3, R4, R2′, R3′, R4′, R5, and X is —CHR— are as defined in the specification. The invention also provides pharmaceutically acceptable acid addition salts, optically pure enantiomers, racemates and diastereomeric mixtures of such compounds. The invention further provides methods for the treatment of Alzheimer's disease or common cancers.

    摘要翻译: 本发明涉及通式的化合物,其中R 1,R 2,R 3,R 4,R 2, R 3',R 4',R 5和X是-CHR-如说明书中所定义。 本发明还提供药学上可接受的酸加成盐,光学纯对映体,外消旋体和这些化合物的非对映体混合物。 本发明还提供了治疗阿尔茨海默病或常见癌症的方法。

    Sulfonamides
    6.
    发明授权
    Sulfonamides 失效
    磺胺类

    公开(公告)号:US07253158B2

    公开(公告)日:2007-08-07

    申请号:US11179703

    申请日:2005-07-12

    CPC分类号: C07D223/12 C07D403/12

    摘要: The invention relates to compounds of the general formula in which R1, R2, R3, R4, R2′, R3′, R4′, R5, and X is —CHR— are as defined in the specification. The invention also provides pharmaceutically acceptable acid addition salts, optically pure enantiomers, racemates and diastereomeric mixtures of such compounds. The invention further provides methods for the treatment of Alzheimer's disease or common cancers.

    摘要翻译: 本发明涉及通式的化合物,其中R 1,R 2,R 3,R 4,R 2, R 3',R 4',R 5和X是-CHR-如说明书中所定义。 本发明还提供药学上可接受的酸加成盐,光学纯对映体,外消旋体和这些化合物的非对映体混合物。 本发明还提供了治疗阿尔茨海默病或常见癌症的方法。

    Pyridines
    9.
    发明授权
    Pyridines 有权
    吡啶类

    公开(公告)号:US08415379B2

    公开(公告)日:2013-04-09

    申请号:US12768762

    申请日:2010-04-28

    IPC分类号: A61K31/443 C07D413/14

    摘要: The present invention is concerned with isoxazole-pyridines of formula I, having affinity and selectivity for GABA A α5 receptor, their manufacture, pharmaceutical compositions containing them and their use as pharmaceuticals. The active compounds of the present invention are useful as cognitive enhancer or for the therapeutic and/or prophylactic treatment of cognitive disorders like Alzheimer's disease.

    摘要翻译: 本发明涉及式I的异恶唑 - 吡啶,对GABA Aα5受体具有亲和性和选择性,其制备方法,含有它们的药物组合物及其作为药物的用途。 本发明的活性化合物可用作认知增强剂或用于治疗和/或预防性治疗认知障碍如阿尔茨海默氏病。

    Pyridines
    10.
    发明授权
    Pyridines 有权
    吡啶类

    公开(公告)号:US08357703B2

    公开(公告)日:2013-01-22

    申请号:US12772250

    申请日:2010-05-03

    IPC分类号: A61K31/4427 C07D413/12

    CPC分类号: C07D413/12 C07D413/14

    摘要: The present invention is concerned with novel isoxazoles of formula I wherein X, R1, R2, R3 and R4 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. The active compounds of the present invention have affinity and selectivity for GABA A α5 receptor. Further the present invention is concerned with the manufacture of the active compounds of formula I, pharmaceutical compositions containing them and their use as therapeutics.

    摘要翻译: 本发明涉及式I的新异恶唑,其中X,R 1,R 2,R 3和R 4如本文所述,以及其药学上可接受的盐和酯。 本发明的活性化合物对GABA Aα5受体具有亲和性和选择性。 此外,本发明涉及制备式I的活性化合物,含有它们的药物组合物及其作为治疗剂的用途。